EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study

Qingqing Gao, Haowen Lin, Zewen Zhao, Siqi Peng, Qiong Wu, Xiaoying Dong, Yuhe Yin, Lixia Xu, Jianchao Ma, Yiming Tao, Zhonglin Feng, Shuangxin Liu und 1 weitere

International Urology and Nephrology · 2025

DOI: 10.1007/s11255-025-04512-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Qingqing Gao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangdong, 5100…. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Planning Project of Guangzhou, Guangdong Medical Science and Technology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The proteinuria is closely related to the prognosis of IgA nephropathy (IgAN) patients. Finerenone has been demonstrated to reduce proteinuria in diabetic kidney disease (DKD). However, the role of finerenone in IgAN has not been reported. This study is to analyze the efficacy and safety of finerenone in IgAN. METHODS: This retrospective study analyzed IgAN patients' data post-finerenone treatment, with groups defined by treatment plans at baseline. It observed changes in the urinary albumin-to-creatinine ratio (UACR), the estimated glomerular filtration rate (eGFR), and serum potassium (sK+) levels over a 3-6 months follow-up. RESULTS: Totally 49 patients had follow-up data at 3 months, and 21 of which had data at 6 months. The median UACR at baseline was 494.25 mg/g. At 1 month, the median UACR decreased by 113 mg/g. At 3 months, the median UACR further decreased by 236.19 mg/g, and the median decrease percentage was 42.29%. At 6 months, the median UACR decreased by 203.88 mg/g, with the median decrease percentage of 41.86%. The average eGFR at baseline was 64.14 ± 19.74 mL/min/1.73 m2. At 6 months, the eGFR showed a minor increase, although it was not statistically significant. The sK+ levels remained within the normal range from 3 to 6 months. CONCLUSIONS: This real-world study demonstrated the efficacy and safety of finerenone treatment in IgAN patients during a 3-6 months follow-up period, providing clinical evidence to support its use in IgAN. However, further prospective research is needed to prove these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAMineralocorticoid Receptor AntagonistsHumansRetrospective StudiesMaleFemaleAdultMiddle AgedTreatment OutcomeGlomerular Filtration RateCreatininePotassiumNaphthyridines

Stichwörter der Autor:innen

EffectivenessFinerenoneIgA NephrologyProteinuriaSafety

Substanzen

finerenoneMineralocorticoid Receptor AntagonistsCreatininePotassiumNaphthyridines

Autor:innen und Institutionen

  • Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangdong, 510000, China.
  • Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong, 510000, China.
  • Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangdong, 510000, China. 13543456446@139.com.
  • Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangdong, 510000, China. dreammore@139.com.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Planning Project of Guangzhou
  • Guangdong Medical Science and Technology Research Foundation
  • Guangzhou Municipal Science and Technology Plan Project
  • Natural Science Foundation of Guangdong Province
  • Project supported by the KPT Plan of Guangdong Medical Development Foundation

Zitieren

APA

Gao, Q., Lin, H., Zhao, Z., Peng, S., Wu, Q., Dong, X., Yin, Y., Xu, L., Ma, J., Tao, Y., Feng, Z., Liu, S., & Wen, F. (2025). Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04512-3

Vancouver

Gao Q, Lin H, Zhao Z, Peng S, Wu Q, Dong X, et al. Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04512-3

BibTeX
@article{Gao2025,
  author = {Gao, Qingqing and Lin, Haowen and Zhao, Zewen and Peng, Siqi and Wu, Qiong and Dong, Xiaoying and Yin, Yuhe and Xu, Lixia and Ma, Jianchao and Tao, Yiming and Feng, Zhonglin and Liu, Shuangxin and Wen, Feng},
  title = {Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study},
  journal = {International Urology and Nephrology},
  year = {2025},
  doi = {10.1007/s11255-025-04512-3}
}
Kostenlos starten →